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Introduction
Superior vena cava (SVC) syndrome results from ob-
struction of SVC. Malignancy accounts for more than 90%
of causes of obstruction. The most common malignant cases
are non-small cell lung cancer (50%), small cell lung cancer
(25%) and lymphoma (12%) (1,2). On the other hands, adult
T-cell leukemia/lymphoma (ATL) usually runs an aggressive
course with multiple organs involvement (3). Here, we report
a rare case of SVC syndrome as the earliest symptom of ATL.
Case report
A 74-year-old man with a smoking history was admitted
for back and right arm pain. On examination, swelling of the
face and arms and prominent spidery telangiectasia on his
anterior chest were noted: the jugular veins were nonpulsatile
and distended. Chest X-ray and contrast-enhanced computed
tomographic imaging of the chest demonstrated a bulky
(10.0 x 7.2 cm) tumor with a low-density area in the right
upper mediastinum (Figure 1). The lesion invaded the anterior
chest wall and compressed the superior vena cava. CT-guided
transcutaneous mediastinal biopsy was performed, and diffuse
and invasively progressed small round cells and atypical lym-
phocytes were found (Figure 2). Immunostaining of the same
samples was positive for both UCHL1 and CD3, which indi-
cate T-cells. Both L26 and CD79a, which indicate B-cells,
were negative. CD79a is not shown. Pathological diagnosis
was malignant lymphoma, diffuse, T-cell type. We then in-
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A 74-year-old man with a smoking history was admitted for back and right arm pain. On examination, swelling of the face
and arms were noted, and computed tomographic imaging of the chest demonstrated a bulky (10.0 x 7.2 cm) tumor in the right
upper mediastinum. The lesion compressed the superior vena cava (SVC). Despite treatment, the patient died 5 months after
the first admission. On autopsy, he was diagnosed that SVC syndrome caused by adult T-cell leukemia/lymphoma (ATL). ATL
usually runs an aggressive course with multiple organs involving lymph nodes, liver, spleen, skin, lung, peripheral blood and
bone marrow. Although it is extremely rare, SVC syndrome can appear as the earliest symptom of ATL.
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vestigated the blood sample data, which showed elevation
of human T-cell leukemia virus type 1 (HTLV-1) antibody,
LDH (1063 IU/l) and soluble IL-2 receptor (4643 U/ml).
Therefore, we clinically diagnosed the patient as having su-
perior vena cava (SVC) syndrome caused by adult T-cell
leukemia/lymphoma (ATL), lymphoma type (3). There
were no abnormal lymphocytes in peripheral blood, no bone
marrow suppression, no skin lesions, no lymphnode swel-
ling at other sites than mediastinum, and no enlargement of
liver and spleen. Despite treatment including chemotherapy
consisted by therarubicin, cyclophosphamide, vincristine,
irinotecan and carboplatin, and thoracic radiotherapy, the
patient died 5 months after the first admission. On autopsy,
a sample of renal lesion was examined by southern blot
analysis (Figure 3). The HTLV-1 provirus was detected and
the final diagnosis of ATL was confirmed.
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Figure 1. a) Chest X-ray on admission, showing a huge tumor in the right upper
mediastinum. b) CT image of the chest on admission, showing a huge tumor with low-
density area, invading the anterior chest wall and compressing the superior vena cava.
Figure 2. H.E. staining and immunostaining of the CT-guided transcutaneous mediastinal
biopsy samples (high-power view). Both UCHL1 and CD3, which indicate T-cells, were
positive. Both L26 and CD79a, which indicate B-cells, were negative. CD79a is not shown.
Figure 3. Southern blot analysis using DNA extracted from the
renal tissue at autopsy was positive for HTLV-1 proviral integra-
tion. M: size marker (λDNA/Hind III), 1: positive control (mono-
clonal integrated DNA), 2: negative control, 3: sample. Restriction
enzyme E: Eco RI digestion, P: Pst I digestion.
Takaya Ikeda et al.: SVC syndrome caused by ATL
Discussion
ATL is an aggressive malignancy of CD4+ T-cell lym-
phoid caused by HTLV-1 infection (4). Transmission of
HTLV-1 by blood transfusion, needle sharing, breast feed-
ing, and from male to female (rarely the reverse) by sexual
intercourse has been documented (5). The interval between
HTLV-1 infection and the onset of lymphoma is long (10-
40 years) and only less than 5% of infected people actually
develop to ATL. SVC syndrome is the clinical expression
of obstruction of blood flow through the SVC (6). The most
common malignant lesions are lung cancer and lymphoma.
Since the tumor cells aggressively infiltrate multiple or-
gans, commonly involving lymph nodes, liver, spleen, skin,
and lung in ATL, it is extremely rare that the disease appear
in only right upper mediastinum and SVC syndrome as the
earliest symptom.
The differential diagnosis of ATL includes mycosis fungoides,
Sezary syndrome, Hodgkin's lymphoma, and T-cell chronic
lymphocytic leukemia. In our case, HTLV-I seropositivity,
negative L26 and CD79a staining, and positive UCHL1 and
CD3 staining support ATL diagnosis. Detection of integrated
HTLV-1 provirus by southern blot analysis on autopsy made
the diagnosis definitive.
SVC syndrome due to malignancy produces acute dis-
tress and degrades the quality of life during the limited sur-
vival (6). Endovascular stents have been used successfully
as a relatively new option and provide relief of the symp-
toms (7). In our case, we could achieve relief of symptoms
of SVC syndrome by first line chemotherapy and second
line chemoradiotherapy. Endovascular stents after second
line therapy were not applicable because of systemic pro-
gression of ATL. Multiagent chemotherapy usually attains
only partial, short lasting response in ATL. Since the dis-
ease is not curable at present, prenatal HTLV-1 screening
and cessation of breast-feeding by HTLV-1-infected women
may suppress disease progression.
In conclusion, we report the first case of SVC syndrome
caused by ATL. Although it is extremely rare, SVC syn-
drome can appear as the earliest symptom of ATL.
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